Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$80.54K-$80.54KN/M vs Q1 2025 EPS Diluted$0.00$0.00— vs Q1 2025 Operating Income-$69,147N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
ended Apr 30, 2025 · filed Jun 15, 2026 · 411 d after period end